(MENAFN- ProactiveInvestors)
Limited () has received approval from the Trial Safety Committee and the Royal Adelaide Hospital Ethics Committee to escalate the dose of its PPL-1 cancer treatment in patients.
This follows completion of treatment of the lowest dose patient cohort (5mg/kg) during recent months that resulted in a low and acceptable adverse event profile and demonstration of inhibitory activity on a key tumour marker.
The escalation in dose will be a 5-fold increase to 25mg/kg in accordance with the protocol approved in 2014.
In addition the company has committed to developing a tasteless capsule formulation of PPL-1 to facilitate higher doses in both the present and future trials.
The Trial Safety Committee noted that as the quantity of drug being consumed orally increases with escalating doses there may be some challenges in patients tolerating the treatment due to the taste.
The cancer chemotherapy market (estimated at $42 billion/annum) is currently the fastest growing sector within the pharma industry mainly driven by the identification of new potential therapeutic targets.
This growth is further fuelled by the magnitude of the disease worldwide currently estimated at more than 25 million people suffering from cancer globally and an estimated 5 million people dying each year from the disease.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.